General practitioners should be conducting targeted screening for dementia in people aged 65 to 74

Steve Iliffe
Professor of Primary Care for Older People, Department of Primary Care and Population Health, University College London, Rowland Hill St, London NW3 2PF, UK
s.iliffe@ucl.ac.uk

There is no doubt that dementia syndrome is important. It costs the health and social services more than cancer, heart disease and stroke combined, and its prevalence is rising. It is a syndrome of symptoms that includes a range of neurodegenerative disorders that share two common features: they are progressive, and no disease-modifying treatments are available for them despite decades of research. The survival time for most people who develop dementia is short, being 4.5–5 years from symptom onset to 3.5 years from diagnosis, making dementia a condition in need of palliation.

Risk factors for dementia are similar to those of cardiovascular disease, but with some evidence of genetic vulnerability, especially in those who acquire the syndrome relatively early in life. As yet, there are no disease markers available for population screening.

Mild cognitive impairment, the presumed prodromal state of dementia syndrome, is problematic...
because a proportion of those with it revert to ‘normal’ cognitive function. The natural course of dementia is supposedly different between dementia subtypes (Alzheimer’s disease, vascular dementia, and so on) but these clinical descriptions overlap and the ‘natural history’ varies greatly.

No primary prevention interventions have been consciously implemented, but the incidence of dementia seems to be declining, possibly because of systematic medical attention to cardiovascular risk factors.

The diagnostic test

There must be a simple, safe, precise and validated screening test that is acceptable to the population. There should be an agreed policy on the further diagnostic investigation of individuals with a positive test result.

The currently available medical treatments (the cholinesterase inhibitors and memantine) produce small changes in cognitive function in some people with dementia, but at the population level their clinical benefits are probably negligible.

Although questions about memory problems have been included in general practice (GP) screening in the United Kingdom (UK), they are a poor predictor of who gets dementia syndrome. Palmer’s Swedish study demonstrated that asking questions about memory, using the mini-mental state examination (MMSE) as a second-stage screening question, and following up those with lower MMSE scores, identified less than one in five of those who subsequently developed dementia. Subjective memory complaints are common in the older population, and are associated with depression, trait anxiety and physical frailty.

A recent systematic review concluded that there are few brief cognitive function tests with good performance available for use in primary care, the exception being the MMSE, which has the longest administration time and is not free for public use. Most brief instruments had been validated in only one community-based study.

In the UK, there is agreed policy in investment in memory clinics to further diagnostic investigations, even though there is little evidence to support this form of service organisation, other than self-evaluations of innovative clinics. Expansion of memory clinics in the National Health Service in the UK has been substantial.

Effective treatment

There should be an effective treatment for patients identified through early detection, with evidence of early rather than late treatment leading to better outcomes. This evidence should come from high-quality randomised controlled trials showing that the screening programme is effective in reducing morbidity. The benefit from the screening programme should outweigh the physical and psychological harm (caused by the test, diagnostic procedures and treatment). All other options for managing the condition should have been considered (e.g. improving treatment, providing other services), to ensure that no more cost-effective intervention could be introduced within the resources available.

There is no evidence available that suggests that earlier diagnosis affects clinician, patient or family decision-making. The trials have simply not been carried out. The currently available medical treatments (the cholinesterase inhibitors and memantine) produce small changes in cognitive function in some people with dementia, but at the population level their clinical benefits are probably negligible.

Complex non-pharmacological interventions, like cognitive stimulation and exercise, can show...
small beneficial effects for patients or carers, but the availability of such complex interventions is limited. There are no experimental studies to refute or confirm harms of screening. Other options for responding to dementia syndrome have not been debated in the UK.

Costs

The opportunity cost of the screening programme (including testing, diagnosis and treatment, administration, training and quality assurance) should be economically balanced in relation to expenditure on medical care as a whole (i.e. value for money). Adequate staffing and facilities for testing, diagnosis, treatment and programme management should be available prior to the commencement of the screening programme.

No economic evaluations of dementia screening have been carried out, but there has been pressure to secure funding for testing and diagnosis programmes, which are now incentivised in general practice as part of the Quality and Outcomes Framework.

Conclusions

We need to understand the true balance of benefits and harms of dementia screening, especially given the small, uncertain benefits of treatment seen on continuous measures of cognitive function or carer burden. Screening programmes for dementia should not have been introduced until we had measured their benefits and harms, and learned more about the impact of therapies.

General practitioners should instead enhance their diagnostic skills, aiming to recognise the features of dementia syndrome as it emerges in individual patients, and acquire the repertoire of responses that serve the best interests of their patients, and of family carers. The challenge is to minimise misattribution of cognitive or behavioural changes to ageing or personality, and to respond in a timely way to the concerns of people with dementia symptoms, and their families. These may be difficult tasks, but they do not reduce the practitioner to a screening technician, operating a potentially flawed system.

References


COMPETING INTERESTS
Recipient of research funding from the UK government and the European Commission for dementia studies.

Former Associate Director of the UK Dementias and Neurodegenerative Diseases Research Network (DEndRON).

Member of the NICE Dementia Clinical guidelines development group 2004-6.